GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Net Current Asset Value

Abionyx Pharma (XPAR:ABNX) Net Current Asset Value : €0.00 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Abionyx Pharma's net current asset value per share for the quarter that ended in Dec. 2023 was €0.00.

The historical rank and industry rank for Abionyx Pharma's Net Current Asset Value or its related term are showing as below:

During the past 11 years, the highest Price-to-Net-Current-Asset-Value Ratio of Abionyx Pharma was 34.93. The lowest was 1.13. And the median was 4.15.

XPAR:ABNX's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.765
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Abionyx Pharma Net Current Asset Value Historical Data

The historical data trend for Abionyx Pharma's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma Net Current Asset Value Chart

Abionyx Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.26 0.07 -0.04 -

Abionyx Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 - -0.04 -0.12 -

Competitive Comparison of Abionyx Pharma's Net Current Asset Value

For the Biotechnology subindustry, Abionyx Pharma's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abionyx Pharma's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's Price-to-Net-Current-Asset-Value falls into.



Abionyx Pharma Net Current Asset Value Calculation

Abionyx Pharma's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(A: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(6.886-6.912-0-0)/32.1916
=-0.00

Abionyx Pharma's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(6.886-6.912-0-0)/32.1916
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abionyx Pharma  (XPAR:ABNX) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Abionyx Pharma Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Abionyx Pharma (XPAR:ABNX) Business Description

Traded in Other Exchanges
Address
33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (XPAR:ABNX) Headlines

No Headlines